Latest RA CAPITAL MANAGEMENT, L.P. Stock Portfolio
RA CAPITAL MANAGEMENT, L.P. Performance:
2025 Q3: 16.58%YTD: -5.28%2024: 6.22%
Performance for 2025 Q3 is 16.58%, and YTD is -5.28%, and 2024 is 6.22%.
About RA CAPITAL MANAGEMENT, L.P. and 13F Hedge Fund Stock Holdings
RA CAPITAL MANAGEMENT, L.P. is a hedge fund based in BOSTON, MA. On 03-Apr-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $9.7 Billions. In it's latest 13F Holdings report, RA CAPITAL MANAGEMENT, L.P. reported an equity portfolio of $8.1 Billions as of 30 Sep, 2025.
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , RYTM, PCVX. The fund has invested 25.2% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 7.1% of portfolio in RHYTHM PHARMACEUTICALS INC.
The fund managers got completely rid off DYNE THERAPEUTICS INC (DYN), VOR BIOPHARMA INC (VOR) and RXSIGHT INC (RXST) stocks. They significantly reduced their stock positions in AVALO THERAPEUTICS INC (AVTX). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in NUVALENT INC-A (NUVL), VOR BIOPHARMA INC (VOR) and BELITE BIO INC - ADR. The fund showed a lot of confidence in some stocks as they added substantially to PEPGEN INC (PEPG), MINERALYS THERAPEUTICS INC and AVIDITY BIOSCIENCES INC (RNA).
The top stock holdings of RA CAPITAL MANAGEMENT, L.P. are , RYTM, PCVX. The fund has invested 25.2% of it's portfolio in ASCENDIS PHARMA A/S - ADR and 7.1% of portfolio in RHYTHM PHARMACEUTICALS INC.
The fund managers got completely rid off DYNE THERAPEUTICS INC (DYN), VOR BIOPHARMA INC (VOR) and RXSIGHT INC (RXST) stocks. They significantly reduced their stock positions in AVALO THERAPEUTICS INC (AVTX). RA CAPITAL MANAGEMENT, L.P. opened new stock positions in NUVALENT INC-A (NUVL), VOR BIOPHARMA INC (VOR) and BELITE BIO INC - ADR. The fund showed a lot of confidence in some stocks as they added substantially to PEPGEN INC (PEPG), MINERALYS THERAPEUTICS INC and AVIDITY BIOSCIENCES INC (RNA).
RA CAPITAL MANAGEMENT, L.P. Annual Return Estimates Vs S&P 500
Our best estimate is that RA CAPITAL MANAGEMENT, L.P. made a return of 16.58% in the last quarter. In trailing 12 months, it's portfolio return was -12.38%.
New Buys
| Ticker | $ Bought |
|---|---|
| nuvalent inc-a | 107,794,000 |
| vor biopharma inc | 96,577,700 |
| belite bio inc - adr | 64,750,000 |
| lb pharmaceuticals inc | 28,058,200 |
| assembly biosciences inc | 26,122,500 |
| contineum therapeutics inc-a | 24,933,500 |
| invivyd inc | 18,831,000 |
| prime medicine inc | 16,620,000 |
New stocks bought by RA CAPITAL MANAGEMENT, L.P.
Additions
| Ticker | % Inc. |
|---|---|
| pepgen inc | 87.7 |
| mineralys therapeutics inc | 19.14 |
| avidity biosciences inc | 18.92 |
| edgewise therapeutics inc | 5.31 |
| scholar rock holding corp | 2.67 |
| rhythm pharmaceuticals inc | 2.16 |
| solid biosciences inc | 0.00 |
Additions to existing portfolio by RA CAPITAL MANAGEMENT, L.P.
Reductions
| Ticker | % Reduced |
|---|---|
| avalo therapeutics inc | -28.94 |
RA CAPITAL MANAGEMENT, L.P. reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| dyne therapeutics inc | -92,481,000 |
| rxsight inc | -48,138,600 |
| tourmaline bio inc | -40,597,400 |
| vor biopharma inc | -64,226,600 |
| protara therapeutic inc | -3,149,060 |
| enliven therapeutics inc | -17,030,700 |
| beta bionics inc | -7,280,000 |
| 10x genomics inc-class a | -5,504,470 |
RA CAPITAL MANAGEMENT, L.P. got rid off the above stocks
Sector Distribution
RA CAPITAL MANAGEMENT, L.P. has about 53.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 53.3 |
| Others | 45.1 |
| 1.7 |
Market Cap. Distribution
RA CAPITAL MANAGEMENT, L.P. has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 48.7 |
| MID-CAP | 26.1 |
| SMALL-CAP | 17 |
| MICRO-CAP | 7.3 |
Stocks belong to which Index?
About 40.2% of the stocks held by RA CAPITAL MANAGEMENT, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 59.8 |
| RUSSELL 2000 | 40.2 |
RA CAPITAL MANAGEMENT, L.P. Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of RA CAPITAL MANAGEMENT, L.P.
RA CAPITAL MANAGEMENT, L.P. has 67 stocks in it's portfolio. About 63.9% of the portfolio is in top 10 stocks. SBTX proved to be the most loss making stock for the portfolio. RYTM was the most profitable stock for RA CAPITAL MANAGEMENT, L.P. last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABOS | acumen pharmaceuticals inc | 0.32 | 14,932,100 | 25,533,800 | unchanged | 0.00 | ||
| ACET | adicet bio inc | 0.07 | 7,541,000 | 6,109,720 | unchanged | 0.00 | ||
| ACHC | acadia healthcare co inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACLX | arcellx inc | 3.07 | 3,036,530 | 249,299,000 | unchanged | 0.00 | ||
| ADGI | invivyd inc | 0.23 | 17,119,100 | 18,831,000 | new | |||
| ASMB | assembly biosciences inc | 0.32 | 1,020,410 | 26,122,500 | new | |||
| AVTE | jade biosciences inc | 0.11 | 1,062,330 | 9,167,870 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.10 | 662,968 | 8,426,320 | reduced | -28.94 | ||
| CDTX | cidara therapeutics inc | 3.97 | 3,365,520 | 322,282,000 | unchanged | 0.00 | ||
| CTMX | cytomx therapeutics inc | 0.10 | 2,661,330 | 8,489,650 | unchanged | 0.00 | ||
| DSGN | design therapeutics inc | 0.04 | 475,699 | 3,582,010 | new | |||
| DYN | dyne therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ELDN | eledon pharmaceuticals inc | 0.11 | 3,566,340 | 9,236,820 | unchanged | 0.00 | ||
| ELYM | climb bio inc | 0.78 | 31,419,300 | 63,152,700 | unchanged | 0.00 | ||
| ETNB | 89bio inc | 3.60 | 19,889,700 | 292,378,000 | unchanged | 0.00 | ||
| EVH | evolent health inc - a | 0.06 | 579,052 | 4,898,780 | new | |||
| EWTX | edgewise therapeutics inc | 2.08 | 10,428,400 | 169,149,000 | added | 5.31 | ||
| EXAS | exact sciences corp | 0.04 | 54,939 | 3,005,710 | new | |||
| FDMT | 4d molecular therapeutics in | 0.49 | 4,563,210 | 39,654,300 | unchanged | 0.00 | ||
| FULC | fulcrum therapeutics inc | 1.16 | 10,229,100 | 94,107,700 | unchanged | 0.00 | ||